Literature DB >> 23847024

Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7-10 years.

Shahed Iqbal1, John P Barile, William W Thompson, Frank DeStefano.   

Abstract

PURPOSE: Concerns have been raised that children may be receiving too many immunizations under the recommended schedule in the USA. We used a publicly available dataset to evaluate the association between antibody-stimulating proteins and polysaccharides from early childhood vaccines and neuropsychological outcomes at age 7-10 years.
METHODS: Children aged 7-10 years from four managed care organizations underwent standardized tests for domain-specific neuropsychological outcomes: general intellectual function, speech and language, verbal memory, attention and executive function, tics, achievement, visual spatial ability, and behavior regulation. Vaccination histories up to 24 months of age were obtained from medical charts, electronic records, and parents' records. Logistic regressions and structural equation modeling (SEM) were used to determine associations between total antigens up to 7, 12, and 24 months and domain-specific outcomes.
RESULTS: On average, children (N = 1047) received 7266, 8127, and 10 341 antigens by ages 7, 12, and 24 months, respectively. For adjusted analyses, increase (per 1000) in the number of antigens was not associated with any neuropsychological outcomes. Antigen counts above the 10th percentile, compared with lower counts, were also not associated with any adverse outcomes. However, children with higher antigen counts up to 24 months performed better on attention and executive function tests (odds ratio for lower scores = 0.51, 95% confidence interval = 0.26, 0.99). Similar results were found with SEM analysis (b = 0.08, p = 0.02).
CONCLUSIONS: We did not find any adverse associations between antigens received through vaccines in the first two years of life and neuropsychological outcomes in later childhood. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  antigens; child health; epidemiology; neuropsychology; pediatrics; pharmacoepidemiology

Mesh:

Substances:

Year:  2013        PMID: 23847024     DOI: 10.1002/pds.3482

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  5 in total

Review 1.  [Postvaccinal complications and management of suspected cases].

Authors:  Doris Oberle; Dirk Mentzer; Fabia Rocha; Renz Streit; Karin Weißer; Brigitte Keller-Stanislawski
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

2.  Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age.

Authors:  Jason M Glanz; Sophia R Newcomer; Matthew F Daley; Frank DeStefano; Holly C Groom; Michael L Jackson; Bruno J Lewin; Natalie L McCarthy; David L McClure; Komal J Narwaney; James D Nordin; Ousseny Zerbo
Journal:  JAMA       Date:  2018-03-06       Impact factor: 56.272

3.  The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes.

Authors:  Jason M Glanz; Christina L Clarke; Matthew F Daley; Jo Ann Shoup; Simon J Hambidge; Joshua T B Williams; Holly C Groom; Elyse O Kharbanda; Nicola P Klein; Lisa A Jackson; Bruno J Lewin; David L McClure; Stanley Xu; Frank DeStefano
Journal:  Pediatrics       Date:  2021-12-01       Impact factor: 9.703

Review 4.  Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines.

Authors:  José G Dórea
Journal:  Neurochem Res       Date:  2017-04-24       Impact factor: 3.996

Review 5.  Vaccine safety issues at the turn of the 21st century.

Authors:  Laura Conklin; Anders Hviid; Walter A Orenstein; Andrew J Pollard; Melinda Wharton; Patrick Zuber
Journal:  BMJ Glob Health       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.